Literature DB >> 26541076

The EMPA-REG study: What has it told us? A diabetologist's perspective.

Ralph A DeFronzo1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26541076      PMCID： PMC4888368          DOI： 10.1016/j.jdiacomp.2015.10.013

Source DB:  PubMed          Journal:  J Diabetes Complications        ISSN： 1056-8727            Impact factor:   2.852


× No keyword cloud information.
  14 in total

1.  Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.

Authors:  Bryan Williams; Peter S Lacy; Simon M Thom; Kennedy Cruickshank; Alice Stanton; David Collier; Alun D Hughes; H Thurston; Michael O'Rourke
Journal:  Circulation       Date:  2006-02-13       Impact factor: 29.690

2.  Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.

Authors:  Anushka Patel; Stephen MacMahon; John Chalmers; Bruce Neal; Laurent Billot; Mark Woodward; Michel Marre; Mark Cooper; Paul Glasziou; Diederick Grobbee; Pavel Hamet; Stephen Harrap; Simon Heller; Lisheng Liu; Giuseppe Mancia; Carl Erik Mogensen; Changyu Pan; Neil Poulter; Anthony Rodgers; Bryan Williams; Severine Bompoint; Bastiaan E de Galan; Rohina Joshi; Florence Travert
Journal:  N Engl J Med       Date:  2008-06-06       Impact factor: 91.245

Review 3.  Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes.

Authors:  Muhammad A Abdul-Ghani; Luke Norton; Ralph A Defronzo
Journal:  Endocr Rev       Date:  2011-05-23       Impact factor: 19.871

4.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

Authors:  Bernard Zinman; Christoph Wanner; John M Lachin; David Fitchett; Erich Bluhmki; Stefan Hantel; Michaela Mattheus; Theresa Devins; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Silvio E Inzucchi
Journal:  N Engl J Med       Date:  2015-09-17       Impact factor: 91.245

5.  Glucose control and vascular complications in veterans with type 2 diabetes.

Authors:  William Duckworth; Carlos Abraira; Thomas Moritz; Domenic Reda; Nicholas Emanuele; Peter D Reaven; Franklin J Zieve; Jennifer Marks; Stephen N Davis; Rodney Hayward; Stuart R Warren; Steven Goldman; Madeline McCarren; Mary Ellen Vitek; William G Henderson; Grant D Huang
Journal:  N Engl J Med       Date:  2008-12-17       Impact factor: 91.245

6.  Effects of intensive glucose lowering in type 2 diabetes.

Authors:  Hertzel C Gerstein; Michael E Miller; Robert P Byington; David C Goff; J Thomas Bigger; John B Buse; William C Cushman; Saul Genuth; Faramarz Ismail-Beigi; Richard H Grimm; Jeffrey L Probstfield; Denise G Simons-Morton; William T Friedewald
Journal:  N Engl J Med       Date:  2008-06-06       Impact factor: 91.245

7.  Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.

Authors:  Peter Gaede; Pernille Vedel; Nicolai Larsen; Gunnar V H Jensen; Hans-Henrik Parving; Oluf Pedersen
Journal:  N Engl J Med       Date:  2003-01-30       Impact factor: 91.245

8.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

9.  Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study.

Authors:  Salim Yusuf; Steven Hawken; Stephanie Ounpuu; Tony Dans; Alvaro Avezum; Fernando Lanas; Matthew McQueen; Andrzej Budaj; Prem Pais; John Varigos; Liu Lisheng
Journal:  Lancet       Date:  2004 Sep 11-17       Impact factor: 79.321

10.  The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus.

Authors:  David Zi Cherney; Bruce A Perkins; Nima Soleymanlou; Ronnie Har; Nora Fagan; Odd Erik Johansen; Hans-Juergen Woerle; Maximilian von Eynatten; Uli C Broedl
Journal:  Cardiovasc Diabetol       Date:  2014-01-29       Impact factor: 9.951
View more
  6 in total

Review 1.  Empagliflozin: A Review in Type 2 Diabetes.

Authors:  James E Frampton
Journal:  Drugs       Date:  2018-07       Impact factor: 9.546

Review 2.  SGLT2 inhibitors in the management of type 2 diabetes.

Authors:  R P Monica Reddy; Silvio E Inzucchi
Journal:  Endocrine       Date:  2016-06-07       Impact factor: 3.633

Review 3.  SGLT2 Inhibitors: Benefit/Risk Balance.

Authors:  André J Scheen
Journal:  Curr Diab Rep       Date:  2016-10       Impact factor: 4.810

Review 4.  Closing the knowledge gap on cardiovascular disease in type 2 diabetes: the EMPA-REG OUTCOME trial and beyond.

Authors:  Elif A Oral
Journal:  Drugs Context       Date:  2016-09-02

5.  Investigating the roles of hyperglycaemia, hyperinsulinaemia and elevated free fatty acids in cardiac function in patients with type 2 diabetes via treatment with insulin compared with empagliflozin: protocol for the HyperCarD2 randomised, crossover trial.

Authors:  Roopameera Thirumathyam; Erik Arne Richter; Jens Peter Goetze; Mogens Fenger; Gerrit Van Hall; Ulrik Dixen; Jens Juul Holst; Sten Madsbad; Niels Vejlstrup; Per Lav Madsen; Nils Bruun Jørgensen
Journal:  BMJ Open       Date:  2022-08-11       Impact factor: 3.006

6.  Empagliflozin: Not just a glorified diuretic.

Authors:  Mathew John
Journal:  Indian J Endocrinol Metab       Date:  2016 Mar-Apr
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.